Patents by Inventor Sherry Parker
Sherry Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210252142Abstract: The present invention includes composition and methods for treating a patient with a known or suspected viral-induced infection, respiratory disorder or exacerbation thereof, or preventing the same, the method comprising: administering to the patient in need thereof a therapeutically effective amount of an agent, wherein the agent comprises at least one of: (a) an activatable pro-IFN-Fc antibody, (b) an anti-viral-associated antibody or anti-epithelial-associated antibody (aVab/aEab)-IFN-Fc fusion protein, wherein the aVab/aEab is an anti-PD-L1, anti-VEGF, or anti-EGFR antibody variable domain, an activatable pro-aVab/aEab-IFN-Fc, an activatable aVab/aEab-pro-IFN-Fc, or pro-aVab/aEab-pro-IFN-Fc; wherein the fusion antibody prodrugs are activatable by proteases upregulated in upper and lower respiratory tracts during viral infection; wherein the preferred route of administration is via nasopharyngeal or oropharyngeal airways, and wherein the administration results in suppression of viral replication causing aType: ApplicationFiled: February 5, 2021Publication date: August 19, 2021Inventors: Yang Wang, Sherry Parker
-
Patent number: 9821093Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: GrantFiled: April 23, 2013Date of Patent: November 21, 2017Assignee: OrbusNeich Medical, Inc.Inventors: Robert John Cottone, Jr., Stephen M. Rowland, Sherry Parker
-
Publication number: 20160287708Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: ApplicationFiled: November 20, 2006Publication date: October 6, 2016Applicant: OrbusNeich Medical, Inc.Inventors: Robert John Cottone, JR., Stephen M. Rowland, Sherry Parker
-
Publication number: 20160136337Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: ApplicationFiled: October 7, 2015Publication date: May 19, 2016Inventors: Robert J. Cottone, JR., Steven M. Rowland, Sherry Parker
-
Patent number: 9320829Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: GrantFiled: December 29, 2011Date of Patent: April 26, 2016Assignee: ORBUSNEICH MEDICAL, INC.Inventors: Robert J. Cottone, Jr., Margaret Yoklavich, Sherry Parker
-
Publication number: 20120172970Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: ApplicationFiled: December 29, 2011Publication date: July 5, 2012Applicant: OrbusNeich Medical, Inc.Inventors: Robert John Cottone, JR., Margaret Yoklavich, Sherry Parker
-
Patent number: 8088060Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: GrantFiled: November 15, 2006Date of Patent: January 3, 2012Assignee: OrbusNeich Medical, Inc.Inventors: Robert John Cottone, Jr., Margaret Yoklavich, Sherry Parker
-
Publication number: 20070129789Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: ApplicationFiled: November 20, 2006Publication date: June 7, 2007Applicant: OrbusNeich Medical, Inc.Inventors: Robert Cottone, Stephen Rowland, Sherry Parker
-
Publication number: 20070128723Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: ApplicationFiled: November 15, 2006Publication date: June 7, 2007Applicant: OrbusNeich Medical, Inc.Inventors: Robert Cottone, Stephen Rowland, Sherry Parker
-
Publication number: 20070123977Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.Type: ApplicationFiled: November 15, 2006Publication date: May 31, 2007Applicant: OrbusNeich Medical, Inc.Inventors: Robert Cottone, Margaret Yoklavich, Sherry Parker
-
Publication number: 20050124685Abstract: Disclosed are compounds that are derivatives of brevetoxin, or PbTx, pharmaceutical formulations comprising the compounds, and methods of administering the compounds to a subject for the treatment of neurotoxic shellfish poisoning or ciguatera fish poisoning, wherein the compounds have general Formulas (I) and (III): wherein R, R1, R2, R3, A, n, and Y are as defined herein for each compound.Type: ApplicationFiled: September 20, 2004Publication date: June 9, 2005Inventors: Daniel Baden, Kathleen Rein, Lynne Fieber, Sherry Parker